Patent · US Active

Stable bortezomib formulations

US9061037B2 · kind B2 · utility

0Cited by

13References

12Claims

0Family size

Assignee

INNOPHARMAX, INC. · TW

Inventors

Kumaresh Soppimath · Colts Neck Township, US
Satish Pejaver · Bound Brook, US
Kanaiyalal R. Patel · Chesterfield, US
Lakkaraju Dasaradhi · Princeton Junction, US
Rama Sodum · Princeton, US
Hari Desu · Plainsboro, US
Navneet Puri · Lebanon, US

Key dates

Filing date	Mar 18, 2011
Grant date	Jun 23, 2015
Priority date	—
Expiry date	Mar 18, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/19
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.